Table 1 Summary of major clinical trials on aerosol measles vaccines presented to the expert group for stage II of the CHNRI process

A.Dilraj et al [46]

MV-Schwarz ( s/c, aerosol),

MV- Edmonston-Zagreb ( s/c, aerosol)

992 participants

5-14 years

Seroconversion rates (defined as four fold increase in antibody level):

EZ Aerosol – 84.7%

EZ sc – 78.8%

SW Aerosol – 22.7%

SW sc – 62.6%

A.Dilraj et al [47]

MV-Schwarz ( s/c),

MV- Edmonston-Zagreb ( s/c, aerosol)

337 participants

5-14 years

Seroconversion (defined as four fold increase in antibody level) at 6 years after revaccination:

EZ Aerosol – 86%

EZ sc – 73%

SW sc – 58%

J.A.Bellanti et al [48]

MV- Edmonston-Zagreb ( s/c, aerosol)

49 participants

6-7 years

The mean Specific anti-measles IgG antibody:

EZ sc - 22.9 ± 4.6

EZ aerosol - 53.4 ± 9.4

Results are reported as mean _ µg/ml ± standard error of the mean

J.V.Bennett et al [49]

MV-Schwarz ( s/c),

MV- Edmonston-Zagreb ( s/c, aerosol)

1624 participants

6-8 years

Change from seronegative to seropositive, >= 120 mIU/ml

EZ aerosol – 65%

EZ sc – 4%

SW sc – 23%

R.M.Wong-Chew et al [50]

MV- Edmonston-Zagreb ( s/c, aerosol)

114 participants

11-13 months

Seroresponse rates as defined by four fold increase in antibody level:

EZ aerosol – 89.8%

EZ sc – 100%

R.M.Wong-Chew et al [51]

MV- Edmonston-Zagreb ( s/c, aerosol)

129 participants

8-10 months

Seroresponse rates as defined by four fold increase in antibody level:

EZ Aerosol – 42%

EZ sc – 67%